Jeffrey Bluestone, PhD

Jeffrey Bluestone, PhD, is the A.W. and Mary Margaret Clausen Distinguished Professor of Metabolism and Endocrinology and Emeritus Distinguished Professor in the Department of Medicine and Diabetes Center at UCSF. Prior, he has been Director of Immune Tolerance Network, Diabetes Center at UCSF, as well as Executive Vice Chancellor and Provost at University of California San Francisco. He is the recipient of the JDRF David Rumbough Award for Scientific Excellence, the Outstanding Mentorship Award from the American Society of Transplantation, among many others. He has been elected to both the American Academy of Arts and Sciences and the National Academy of Medicine.

His work over the past 30 years has been in the field of T-cell activation, co-stimulation, and immune tolerance research. The efforts in his lab have led to the development of multiple pro-tolerogenic immunotherapies, including CTLA4Ig, the first FDA-approved drug targeting T-cell co-stimulation to treat autoimmune disease and organ transplantation; a novel anti-human CD3 antibody being developed to treat type 1 diabetes (T1D); and the first CTLA-4 antagonist drugs approved for the treatment of metastatic melanoma. In recent years, he has focused on the field of regulatory T cells, understanding their biology and use in the control of autoimmunity and cancer including several seminal studies to determine mechanisms and control Treg stability. These efforts in translational research have led to over 400 peer-reviewed publications as well as multiple basic research and clinical research grant awards.